- Overview
- Immunogenicity
- About
- Protected: Assays
- Reid Bioanalytical Forum 2022
- Outsourcing in Clinical Trials East Coast 2022
- Celerion Sell Page 2022
- 6th Obesity & NASH Drug Development Summit
- Poster Presentation
- 15th EBF Open Symposium
- Thank You 2022
- EBF Conference 2021
- DIA 2022
- Copy of Brand Afffffwareness – Linkedin
- Rifampin Alternatives for DDI Studies in Response to Nitrosamine Impurities
- Outsourcing in Clinical Trials Southern California
- Outsourcing In Clinical Trials Europe 2023
- Outsourcing In Clinical Trials & Clinical Trial Supply Israel 2023
- Outsourcing in Clinical Trials East Coast 2023
- SCOPE – Summit For Clinical Ops Executives 2023
- DIA 2023
- ASCPT 2023 Annual Meeting
- WRIB 2023
- RSVP
- Outsourcing in Clinical Trials West Coast 2023
- Outsourcing in Clinical Trials Southern California 2023
- Outsourcing in Clinical Trials New England 2023
- 16th EBF Open Symposium 2023
- At AAPS? Let’s Meet!
- Brand Awareness – Linkedin
- 16th WRIB Conference
- Outsourcing in Clinical Trials West Coast 2022
- Product Labeling Studies – Linkedin
- Outsourcing in Clinical Trials New England 2022
- Outsourcing in Clinical Trials Southern California 2022
- Oxford Global: Biomarkers UK Conference 2021
- ACT for American College of Toxicology
- Celerion Sell Page 2022 Number 2
- Bioanalytical Sciences
- Biomarkers
- Biosimilars
- Careers
- Protected: Celerion Jobs Tempe
- Chromatography
- Contact
- Covid-19
- COVID-19 Blog
- COVID-19 regulatory guidance
- COVID-19 Resources
- EBF quiz
- EBF Thank You
- Equipment List
- Experience
- Expertise
- Gene Therapy
- Home
- Innovations
- Inside the Pharmacy
- Investigators
- Ligand-Binding
- Metabolite Profiling
- Our Scientists
- Peptides/Oligos
- Participate in a Study
- PK/PD
- Pharmacy
- Privacy Policy
- Protected: Quality & Speed
- Request For Proposal
- Resources
- Services
- Test
Applying Biomarkers to Early Clinical Development
Biomarkers are a critical element in achieving better decisions faster in early drug development. When used for statistical comparisons the quality of the bioanalytical assay for a biomarker has a direct impact on the number of participants needed for the study. Celerion develops and validates the right assay for the biomarker, decreasing the timelines and cost of the clinical program.
A successful biomarker program requires scientific expertise, up-to-date regulatory knowledge and operational excellence. Celerion has over 40 years’ experience in performing method development, validation and sample analysis in a regulated environment. Celerion is a partner you can trust to deliver on your biomarker program every time.
We complement our exceptional scientific expertise with state-of-the art technologies in the Celerion laboratories:
- Ligand binding assays such as ELISA, RIA, AlphaLISA, Electrochemiluminescence (ECLA)
- Flow cytometry and cell-based assays
- Multiplex immunoassay platform- Luminex and Meso Scale Discovery
- Enzyme-linked immunospot (ELISpot)
- Liquid chromatography and mass spectrometry (LC_MS/MS)
- Molecular assays and genomics using qPCR
Our wide variety of technology platforms allows us to choose the right technology for your biomarker. Celerion also have extensive experience in applying these technologies in various matrices such as serum, plasma, BAL, saliva, sputum and tissues. Celerion offers three tier biomarker validations based on fit-for-purpose (FFP) approach in a GLP environment that is consistent with all global regulatory guidelines. Celerion also offers biomarker services that in compliance with CLIA regulations.
No matter how complex the assay, our team has the scientific and regulatory expertise to measure your biomarker and to ensure delivery of quality results on time.
Biomarkers to Support Drug Development Studies
A multiplex qPCR assay for zika, dengue, and chikungunya viruses (ZDC) to support on-going vaccine and drug efficacy studies
Contact
Translating Your Science to Medicine.
Partner with us to get fast, actionable data you can rely on.